JP6068787B2 - Tissue paper manufacturing method - Google Patents
Tissue paper manufacturing method Download PDFInfo
- Publication number
- JP6068787B2 JP6068787B2 JP2011218522A JP2011218522A JP6068787B2 JP 6068787 B2 JP6068787 B2 JP 6068787B2 JP 2011218522 A JP2011218522 A JP 2011218522A JP 2011218522 A JP2011218522 A JP 2011218522A JP 6068787 B2 JP6068787 B2 JP 6068787B2
- Authority
- JP
- Japan
- Prior art keywords
- tissue paper
- fragrance
- chemical solution
- microcapsules
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 15
- 239000003094 microcapsule Substances 0.000 claims description 46
- 239000000126 substance Substances 0.000 claims description 39
- 239000003205 fragrance Substances 0.000 claims description 35
- 238000007639 printing Methods 0.000 claims description 20
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims description 17
- 239000002826 coolant Substances 0.000 claims description 14
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 229920001807 Urea-formaldehyde Polymers 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000006210 lotion Substances 0.000 claims description 7
- 229920005862 polyol Polymers 0.000 claims description 6
- 150000003077 polyols Chemical class 0.000 claims description 6
- 229940041616 menthol Drugs 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 235000011194 food seasoning agent Nutrition 0.000 claims description 4
- 239000000243 solution Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000006866 deterioration Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 239000002304 perfume Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 4
- -1 liquid paraffin Chemical class 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 230000005068 transpiration Effects 0.000 description 4
- 229920000877 Melamine resin Polymers 0.000 description 3
- 239000004640 Melamine resin Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 229920002803 thermoplastic polyurethane Polymers 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000007646 gravure printing Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000692870 Inachis io Species 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001131 Pulp (paper) Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000035597 cooling sensation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000008155 medical solution Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000010893 paper waste Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Landscapes
- Paper (AREA)
- Sanitary Thin Papers (AREA)
Description
本発明は、水系のローション薬液が付与されたティシュペーパーの製造方法に関する。 The present invention relates to a process for the production of tissue paper which aqueous lotion chemical has been applied.
ティシュペーパーには、保湿性、柔軟性を付与すべく薬液を塗布したものがある。この種のティシュペーパーには、鼻炎や鼻詰まりによる精神的ストレスを緩和するために、薬液中に清涼感を与える香料を内包したマイクロカプセルを混合することがある。マイクロカプセル化により、香料の常時の蒸散を防止し、鼻かみ時の摩擦等によってマイクロカプセルの外郭が破壊され、内部の香料による効果が発揮されるようにしたものである。 Some tissue papers are coated with chemicals to provide moisture retention and flexibility. In order to relieve mental stress caused by rhinitis or nasal congestion, this type of tissue paper may be mixed with microcapsules containing a fragrance that gives a refreshing sensation in the chemical solution. Microcapsulation prevents the perfume from transpiration at all times, destroys the outer shell of the microcapsule due to friction during nose biting, etc., and exhibits the effect of the internal perfume.
しかし、この種のマイクロカプセル化した香料をティシュペーパーに付与する場合、加工時にマイクロカプセルが壊れやすく、歩留まりが悪いという問題があった。 However, when granting microencapsulated perfumes this kind of tissue paper, the microcapsule during processing corrupted Reya easier, yield is poor.
また、マイクロカプセル化した場合でも、マイクロカプセルの外郭が経時的に劣化等して、香料が蒸散し、製品開封時、使用時に香料による所望の効果が得られないことがあった。 In addition, even when microencapsulated, the outer shape of the microcapsule deteriorates with time, and the fragrance evaporates, and the desired effect of the fragrance may not be obtained when the product is opened or used.
そこで、本発明の主たる課題は、香料・清涼剤を内包したマイクロカプセルを含む薬液を付与したティシュペーパーにおける、上記マイクロカプセルの加工時の耐久性、塗布後の経時劣化性を改善することにある。 Therefore, the main problem of the present invention is to improve the durability at the time of processing of the microcapsules and the deterioration with time after application in the tissue paper to which the chemical liquid containing the microcapsules containing the fragrance / coolant is applied. .
上記課題を解決した本発明は以下のとおりである。 The present invention that has solved the above problems is as follows.
〔請求項1記載の発明〕
香料を内包したマイクロカプセルを含有する水系のローション薬液が塗布されたティシュペーパーの製造方法であって、
香料を1.0重量%以下の冷涼剤及びl−メントールを含むメントール系香料とし、外郭を尿素樹脂とし、香料含有率が15〜55重量%である、平均粒径6〜30μmのマイクロカプセルを、水及びポリオールを含有する薬液中に分散させ、その薬液をティシュペーパー原紙に対して、線数10〜30線、面積率10〜20%の刷版を用いてフレキソ印刷方式により、10〜35重量%の範囲で塗布することを特徴とするティシュペーパーの製造方法。
[Invention of Claim 1 ]
A method for producing tissue paper to which a water-based lotion chemical solution containing a microcapsule containing a fragrance is applied,
A microcapsule having an average particle size of 6 to 30 μm, wherein the fragrance is a menthol-based fragrance containing 1.0% by weight or less of a cooling agent and 1-menthol, the outer shell is urea resin, and the fragrance content is 15 to 55% by weight. The chemical solution is dispersed in a chemical solution containing water and a polyol, and the chemical solution is 10 to 35 by a flexographic printing method using a printing plate having 10 to 30 lines and an area ratio of 10 to 20% with respect to the tissue paper base paper. A method for producing tissue paper, wherein the tissue paper is applied in the range of% by weight.
〔請求項2記載の発明〕
薬液中にマイクロカプセルを1〜10重量%添加する請求項1記載のティシュペーパーの製造方法。
[Invention of Claim 2]
The method for producing tissue paper according to claim 1, wherein 1 to 10% by weight of microcapsules is added to the chemical solution.
〔請求項3記載の発明〕
前記マイクロカプセルとして、周囲温度40〜80℃、周囲気圧1気圧〜30気圧の状況下で72時間以上のシーズニングを行なったものを用いる請求項1又は2記載のティシュペーパーの製造方法。
[Invention of Claim 3 ]
The method for producing tissue paper according to claim 1 or 2 , wherein the microcapsules used are those subjected to seasoning for 72 hours or more under conditions of an ambient temperature of 40 to 80 ° C and an ambient pressure of 1 to 30 atmospheres .
(作用効果)
マイクロカプセルの経時劣化の要因は、水系のローション(保湿系)薬液の保湿性の基となる水酸基によるところがあるが、本発明では、マイクロカプセルの外郭を水酸基による影響を受けない尿素樹脂としたので、マイクロカプセルの経時劣化耐性が向上する。また、本発明では、香料としてl−メントールを用いるが、尿素樹脂は重合密度が高く、l−メントールのような揮発性の高い成分であっても経時的な蒸散を十分に防止できる。
(Function and effect)
The cause of aging degradation of microcapsules is due to the hydroxyl group that is the base of the moisturizing properties of aqueous lotion (humidity retention) chemicals. In addition, the deterioration resistance of microcapsules with time is improved. In the present invention, l-menthol is used as a fragrance, but urea resin has a high polymerization density, and even with a highly volatile component such as l-menthol, transpiration over time can be sufficiently prevented.
また、マイクロカプセルの平均粒径を、6〜30μmとした。この平均粒径とすることで、十分な外郭の膜厚を確保でき強度を向上できる。 Moreover, the average particle diameter of the microcapsules was set to 6 to 30 μm. By setting the average particle size, a sufficient outer film thickness can be secured and the strength can be improved.
また、本発明では、薬液付与の方法として、フレキソ印刷としたことで、マイクロカプセルを破損させずに、十分な量の保湿性分をティシュペーパー原紙に付与することが可能となる。 Further, in the present invention, flexographic printing is used as the chemical solution application method, so that a sufficient amount of moisture retention can be applied to the tissue paper base sheet without damaging the microcapsules.
他方、本発明は、l−メントールと冷涼剤とを含む、清涼感を与える効果の高い香料を用いる。よって、香料の清涼感・爽快感をより感じやすく、従来製品よりも精神的ストレスの緩和効果の高いティシュペーパーが得られる。 On the other hand, this invention uses the fragrance | flavor with a high effect which gives a refreshing feeling containing 1-menthol and a cooling agent. Therefore, it is easier to feel the refreshing and refreshing feeling of the fragrance, and a tissue paper having a higher mental stress mitigating effect than conventional products can be obtained.
そして、上記香料をマイクロカプセル化してティシュペーパー原紙に付与するにあたって、請求項記載の所定の条件を採ることで、経時劣化による早期の香りの抜けの問題のほか、マイクロカプセル転写量のバラつきによる製品ロット間の香気の強さのバラツキ等の不良発生も防止される。 In addition, when the fragrance is microencapsulated and applied to the tissue paper base, by taking the prescribed conditions described in the claims, a product due to variations in microcapsule transfer amount in addition to the problem of early fragrance removal due to deterioration over time Occurrence of defects such as variation in fragrance intensity between lots is also prevented.
なお、本発明の尿素樹脂とは、100%尿素樹脂からなるもののみならず、外郭の主たる構成成分・効果成分が尿素樹脂であるものを含む意味である。 The urea resin of the present invention is meant to include not only those made of 100% urea resin, but also those whose main constituent components / effect components are urea resins.
以上の本発明によれば、マイクロカプセルの加工時の耐久性、塗布後の経時劣化性が改善されたティシュペーパーが提供される。 According to the present invention as described above, tissue paper having improved durability at the time of processing of microcapsules and deterioration with time after application is provided.
以下に本発明にかかるティシュペーパー及びその製造方法を詳述する。
本発明は、ティシュペーパー原紙に、香料を内包したマイクロカプセルを分散させた水系のローション薬液を塗布したものであり、そのティシュペーパーは、薬液の有効成分である保湿成分と上記マイクロカプセルを含むものである。
The tissue paper according to the present invention and the manufacturing method thereof will be described in detail below.
The present invention is obtained by applying a water-based lotion chemical solution in which microcapsules containing a fragrance are dispersed on tissue paper, and the tissue paper includes a moisturizing component that is an active ingredient of the chemical solution and the above microcapsules. .
前記ティシュペーパー原紙は、公知のティシュペーパー原紙の製造方法にしたがって、製造することができる。 The tissue paper base paper can be manufactured according to a known method for manufacturing tissue paper base paper.
但し、本発明に係るティシュペーパー原紙は、JIS P 8124による坪量が10〜18g/m2であるクレープ紙を積層して2プライとしたものであるのが望ましい。また、紙厚(尾崎製作所製ピーコックにより測定)は80〜250μm、好ましくは100〜200μm、より好ましくは130〜180μmとするのが望ましい。JIS P 8113に規定される乾燥引張強度(以下、乾燥紙力ともいう)の縦方向が、2プライで200〜700cN/25mm、好ましくは250〜600cN/25mm、特に好ましくは300〜600cN/25mmとされ、他方、横方向が、2プライで100〜300cN/25mm、好ましくは130〜270cN/25mm、特に好ましくは150〜250cN/25mmとされる。乾燥引張強度が低すぎると、製造時及び使用時の断紙や伸び等のトラブルが発生し易くなり、高過ぎると使用時にごわごわした肌触りとなる。 However, it is desirable that the tissue paper base sheet according to the present invention is a two-ply laminate of crepe paper having a basis weight of 10 to 18 g / m 2 according to JIS P 8124. The paper thickness (measured with a Peacock manufactured by Ozaki Seisakusho) is 80 to 250 μm, preferably 100 to 200 μm, more preferably 130 to 180 μm. The longitudinal direction of the dry tensile strength (hereinafter also referred to as dry paper strength) specified in JIS P 8113 is 200 to 700 cN / 25 mm, preferably 250 to 600 cN / 25 mm, particularly preferably 300 to 600 cN / 25 mm with 2 plies. On the other hand, the transverse direction is set to 100 to 300 cN / 25 mm, preferably 130 to 270 cN / 25 mm, particularly preferably 150 to 250 cN / 25 mm with 2 plies. If the dry tensile strength is too low, troubles such as paper breakage and elongation at the time of production and use are likely to occur, and if it is too high, the touch becomes stiff during use.
また、本発明に係るティシュペーパー原紙は、その原料は公知にものが使用できるが、特に、パルプ原料は、NBKPとLBKPとで構成されているのが好ましい。適宜古紙パルプが配合されていてもよいが、水系のローション薬液との相性がよく、得られるティシュペーパーの風合いの点でも望ましいことから、バージンパルプのNBKPとLBKPのみから構成されているのがよい。その場合の配合割合(JIS P 8120)としては、NBKP:LBKP=20:80〜80:20がよく、特に、NBKP:LBKP=40:60〜70:30が望ましい。 The raw material of the tissue paper base paper according to the present invention may be any known raw material, but the pulp raw material is preferably composed of NBKP and LBKP. Waste paper pulp may be blended as appropriate, but it should be composed only of NBKP and LBKP of virgin pulp because it is compatible with aqueous lotion chemicals and desirable in terms of the texture of the resulting tissue paper. . In this case, the blending ratio (JIS P 8120) is preferably NBKP: LBKP = 20: 80 to 80:20, and particularly preferably NBKP: LBKP = 40: 60 to 70:30.
他方、ティシュペーパー原紙への薬液の塗布は、公知の印刷設備或いは、抄紙設備で製造した複数の原反ロールから連続シートを繰出して積層シートとするプライマシンに印刷装置を設けて行なうことができる。 On the other hand, the chemical solution can be applied to the tissue paper base paper by providing a printing device in a ply machine that draws a continuous sheet from a plurality of raw rolls manufactured by a known printing equipment or paper making equipment to form a laminated sheet. .
本発明では、薬液を塗布するための印刷方式としては、フレキソ印刷方式のものを採用する。薬液塗布方式としては、グラビア印刷方式、スプレー塗布方式が知られるが、グラビア印刷方式では、刷版をドクターブレードにて掻き取る操作が必要であり、その際にマイクロカプセルを破損させるおそれがある。また、スプレー方式では、噴霧時の気化熱により液温が下がることでマイクロカプセルの外郭が硬化或いは高粘度化し、詰まりが発生するおそれがある。本発明では、後述するマイクロカプセルの構成ともあいまって、フレキソ印刷に限定することで、上記問題を回避している。さらに、フレキソ印刷では、樹脂製の刷版をもちい印圧が低いため、マイクロカプセルに過度な負荷が加わらずマイクロカプセルを破損させることがない。また。薬液タンクで一定の液温に保温した状態で、薬液を付与できるため、均一に塗布することが可能であるという利点がある。 In the present invention, a flexographic printing method is used as a printing method for applying the chemical solution. As the chemical solution coating method, a gravure printing method and a spray coating method are known. However, in the gravure printing method, an operation of scraping the printing plate with a doctor blade is necessary, and there is a risk of damaging the microcapsules. Further, in the spray method, the liquid temperature is lowered by the heat of vaporization at the time of spraying, so that the outer shell of the microcapsule is hardened or increased in viscosity, and clogging may occur. In the present invention, in combination with the configuration of the microcapsules described later, the above problem is avoided by limiting to flexographic printing. Furthermore, in flexographic printing, since the printing pressure is low using a resin printing plate, an excessive load is not applied to the microcapsules and the microcapsules are not damaged. Also. Since the chemical liquid can be applied while being kept at a constant liquid temperature in the chemical liquid tank, there is an advantage that it can be applied uniformly.
ここで、本発明においては、フレキソ印刷方式を採用するが、その条件として、後述のマイクロカプセルとの構成の関係で、刷版の線数を5〜40線、面積率を5〜30%とし、より好ましくは、刷版の線数を10〜30線、面積率10〜20%とする。 Here, in the present invention, the flexographic printing method is adopted. As the condition, the number of lines of the printing plate is 5 to 40 lines and the area ratio is 5 to 30% in relation to the configuration with the microcapsules described later. More preferably, the number of lines of the printing plate is 10 to 30 lines and the area ratio is 10 to 20%.
また、薬液の塗布は、ティシュペーパー原紙の両面に対して行なうのが望ましい。そして、本発明における薬液の塗布量は、ティシュペーパー原紙重量(米坪)の10〜35重量%の範囲とする。したがって、薬液塗布量は、片面当たり1.0〜5.25g/m2であるのがよい。なお、10重量%未満であると、保湿剤の効果、マイクロカプセルの効果が発現し難い。35重量%を超えて塗布するのは操業上難しく、また、マイクロカプセルの含有量が多くなりすぎて、過度の香気が発せられるおそれが高まる。 Moreover, it is desirable to apply the chemical solution to both sides of the tissue paper base. And the application quantity of the chemical | medical solution in this invention shall be the range of 10 to 35 weight% of the tissue paper base paper weight (US tsubo). Therefore, the chemical solution coating amount is preferably 1.0 to 5.25 g / m 2 per side. In addition, when it is less than 10% by weight, the effect of the moisturizing agent and the effect of the microcapsule are hardly exhibited. Application exceeding 35% by weight is difficult in terms of operation, and the content of microcapsules becomes too high, which increases the possibility of excessive fragrance.
ここで、本発明に係る薬液は、香料を内包したマイクロカプセルを分散させた水系のローション薬液である。上記にマイクロカプセルを分散させる薬液としては、水及びポリオールを含有するものとする。特には、ポリオールを70〜90%、水分を1〜15%を含むもの、特に好ましくは、さらに機能性薬品を0.01〜22%含むものである。かかる水系薬液は、ティシュペーパー原紙のクレープを伸ばす作用があり、保湿性とともにティシュペーパーの表面の滑らかさをも向上させる。 Here, the chemical solution according to the present invention is an aqueous lotion chemical solution in which microcapsules containing a fragrance are dispersed. The chemical solution for dispersing the microcapsules above contains water and a polyol. In particular, those containing 70 to 90% of polyol and 1 to 15% of water, particularly preferably containing 0.01 to 22% of functional chemicals. Such an aqueous chemical solution has an action of extending the crepe of the tissue paper base paper, and improves the smoothness of the surface of the tissue paper as well as moisture retention.
なお、ポリオールはグリセリン、ジグリセリン、プロピレングリコール、1,3−ブチレングリコール、ポリエチレングリコール、およびその誘導体等の多価アルコール、ソルビトール、グルコース、キシリトール、マルトース、マルチトール、マンニトール、トレハロース等の糖類を含む。 The polyol includes polyhydric alcohols such as glycerin, diglycerin, propylene glycol, 1,3-butylene glycol, polyethylene glycol, and derivatives thereof, and saccharides such as sorbitol, glucose, xylitol, maltose, maltitol, mannitol, and trehalose. .
機能性薬剤としては、柔軟剤、界面活性剤、無機および有機の微粒子粉体、油性成分などがある。柔軟剤、界面活性剤はティシューに柔軟性を与えたり表面を滑らかにしたりする効果があり、アニオン性界面活性剤、カチオン性界面活性剤及び両性イオン界面活性剤を適用する。無機および有機の微粒子粉体は表面を滑らかな肌触りとする。油性成分は滑性を高める働きがあり、流動パラフィン、セタノール、ステアリルアルコール、オレイルアルコール等の高級アルコールを用いることができる。 Functional agents include softeners, surfactants, inorganic and organic fine particle powders, oily components, and the like. Softeners and surfactants have the effect of imparting flexibility to the tissue and smoothing the surface, and anionic surfactants, cationic surfactants and zwitterionic surfactants are applied. Inorganic and organic fine particle powders have a smooth surface. The oil component has a function of improving lubricity, and higher alcohols such as liquid paraffin, cetanol, stearyl alcohol, and oleyl alcohol can be used.
また機能性薬剤としてポリオールの保湿性を維持させる薬剤として親水性高分子ゲル化剤、コラーゲン、加水分解コラーゲン、加水分解ケラチン、加水分解シルク、ヒアルロン酸若しくはその塩、セラミド等の1種以上を任意の組合せ等の保湿剤を加えることができる。 In addition, as a functional agent, one or more of a hydrophilic polymer gelling agent, collagen, hydrolyzed collagen, hydrolyzed keratin, hydrolyzed silk, hyaluronic acid or a salt thereof, ceramide, etc. are optionally selected as agents that maintain the moisture retention of polyol. A moisturizer such as a combination of the above can be added.
また機能性薬剤として香料、各種天然エキス等のエモリエント剤、ビタミン類、配合成分を安定させる乳化剤、薬液の発泡を抑え塗布を安定させるための消泡剤、防黴剤、有機酸などを適宜配合することができる。さらには、ビタミンC、ビタミンEの抗酸化剤を含有させてもよい。 In addition, emollients such as fragrances and various natural extracts, vitamins, emulsifiers that stabilize compounding ingredients, antifoaming agents, antifungal agents, organic acids, etc., that suppress the foaming of chemicals and stabilize application as functional agents. can do. Furthermore, you may contain the antioxidant of vitamin C and vitamin E.
上記成分のうち、グリセリン、プロピレングリコール等の多価アルコールを主成分とする場合には、薬液の粘度、塗布量を安定させる点で、塗布の点で好ましい。 Among the above components, when the main component is a polyhydric alcohol such as glycerin or propylene glycol, it is preferable from the viewpoint of application in terms of stabilizing the viscosity and application amount of the chemical solution.
他方、上記薬液中おけるマイクロカプセルの添加量(配合量)は、1〜10重量%とする。1重量%未満では、香料による効果を発揮させ難く、10重量%を超えると香りが強すぎて、香気及び冷涼効果による使用者の精神的なストレス緩和効果が得られないおそれが高まる。 On the other hand, the addition amount (blending amount) of the microcapsules in the chemical solution is 1 to 10% by weight. If it is less than 1% by weight, it is difficult to exert the effect of the fragrance. If it exceeds 10% by weight, the scent is too strong, and there is a high possibility that the user's mental stress relieving effect due to the fragrance and cooling effect cannot be obtained.
他方、上記薬液中に分散させるマイクロカプセルは、本発明では、平均粒径6〜30μmとする。より、好ましくは、10〜20μmとする。上記範囲外とすると、上述のフレキソ印刷の条件で薬液付与をした際に、負荷による破損やクラックによる香料の漏出が生ずるおそれがあり、また、転写量を安定させることが困難となる。 On the other hand, the microcapsules dispersed in the chemical solution have an average particle size of 6 to 30 μm in the present invention. More preferably, the thickness is 10 to 20 μm. If it is out of the above range, there is a risk that breakage due to load or leakage of fragrance due to cracks may occur when chemicals are applied under the above flexographic printing conditions, and it becomes difficult to stabilize the transfer amount.
他方、本発明ではマイクロカプセル内に内包させる香料として、1.0重量%以下の冷涼剤及びl−メントールを含むメントール系香料を用いる。この香料は、鼻をかんだ際に、メントールの揮発性及び冷涼剤により、皮膚に優れた冷涼感を与えるとともに、メントールの特有の香気によって清涼感のある印象が得られる。なお、冷涼剤の含有量を1.0重量%を超えて含有させても効果の向上が望みがたく、却ってコスト高となるおそれがある。 On the other hand, in the present invention, a menthol-based fragrance containing 1.0% by weight or less of a cooling agent and l-menthol is used as a fragrance included in the microcapsule. This fragrance gives the skin an excellent cooling sensation due to the menthol volatility and the cooling agent when biting the nose, and gives a refreshing impression due to the unique odor of menthol. In addition, even if it contains content of a cooling agent exceeding 1.0 weight%, the improvement of an effect is not hoped for, but there exists a possibility that it may become high on the contrary.
マイクロカプセルにおける香料含有率は15〜55重量%であるのが望ましい。かかる香料含有率であると安定的なマイクロカプセルとすることができる。また、香料による鼻かみ時の効果も十分に発揮される。 The perfume content in the microcapsules is preferably 15 to 55% by weight. With such a fragrance content, a stable microcapsule can be obtained. Moreover, the effect at the time of a nose bite by a fragrance | flavor is fully exhibited.
ここで冷涼剤は、l−メントール以外の既知の冷涼剤を用いることができるが、好ましいものは、分子量250以上600以下かつClogP3.0以上のジカルボン酸エステル化合物である。l−メントールは、揮発性が高くマイクロカプセル内から蒸散しやすいが、上記例示の冷涼剤は、持続性に優れ、マイクロカプセル内からの経時的な蒸散が少ない。よって、上記冷涼剤を用いることで、l−メントールのみと比較して経時的な効果の低下が少ない。なお、ClogPは、水/オクタノール分配係数である。 Here, a known cooling agent other than 1-menthol can be used as the cooling agent, but a preferable one is a dicarboxylic acid ester compound having a molecular weight of 250 or more and 600 or less and a ClogP of 3.0 or more. l-Menthol is highly volatile and easy to evaporate from inside the microcapsule. However, the above-described cooling agent has excellent sustainability and little evaporation from the inside of the microcapsule over time. Therefore, by using the above-mentioned cooling agent, there is little decrease in the effect over time compared to only 1-menthol. ClogP is a water / octanol partition coefficient.
特に、冷涼剤としては、ジカルボン酸エステル化合物のなかでも特に好ましいものを例示すると、下記一般式(1)で示すものである。
他方、本発明に係るマイクロカプセルは、外郭が尿素樹脂のものに限定される。マイクロカプセルの外郭を形成する樹脂は、種々知られるが、よく知られるウレタン樹脂のものは、本発明では、薬液が水及びグリセリンを含むことから、これらの水酸基により容易に劣化するため望ましくない。また、よく知られるメラミン樹脂のものは、このような水酸基による劣化もなく安定するが、硬質であり使用時に外郭が破損し難く、鼻かみ時の肌との摩擦によって、ほどよく破損せず、香気の放出に難がある。 On the other hand, the microcapsules according to the present invention are limited to those having a urea resin outer shell. Various resins forming the outer shell of the microcapsule are known, but those of the well-known urethane resin are not desirable in the present invention because the chemical solution contains water and glycerin, and thus easily deteriorates by these hydroxyl groups. In addition, the well-known melamine resin is stable without degradation due to such hydroxyl groups, but it is hard and the outer shell is difficult to break during use, and it does not break moderately due to friction with the skin at the nose bite, Difficult to release fragrance.
本発明では、上記尿素樹脂の外郭を採用することで、上述のウレタン樹脂、メラミン樹脂の外郭が抱える問題が回避される。さらに、尿素樹脂は、密度(比重)が、1.4〜1.5であり、メラミン樹脂(1.3〜1.4)、ウレタン樹脂(1.1〜1.2)と比較して、密度が高く、香料の経時的な蒸散の防止効果が得られる。本発明では、揮発性の高いl−メントールとジカルボン酸エステル化合物に代表される冷涼剤との相乗によって、高いストレス緩和効果をえる香料を内包するが、特に、l−メントールの揮発性が効果的に防止され、清涼感発現の効果の持続性の高いものとなる。 In this invention, the problem which the outline of the above-mentioned urethane resin and melamine resin has is avoided by employ | adopting the outline of the said urea resin. Furthermore, the urea resin has a density (specific gravity) of 1.4 to 1.5, compared with the melamine resin (1.3 to 1.4) and the urethane resin (1.1 to 1.2). The density is high, and the effect of preventing perfume transpiration over time is obtained. In the present invention, a fragrance having a high stress relieving effect is included by synergy of highly volatile l-menthol and a cooling agent typified by a dicarboxylic acid ester compound. In particular, the volatility of l-menthol is effective. Therefore, the refreshing effect is highly sustained.
ここで、本発明においては、尿素樹脂系の外郭を採用するが、特に好ましくは、カプセル形成後に少なくとも72時間以上、周囲温度40〜80℃、周囲気圧1気圧〜30気圧の状況下で、シーズニングしたものを用いる。製造直後は、内包する香料の蒸散圧、含有水分などによって、マイクロカプセルの外郭が安定していない場合があるが、72時間以上のシーズニングを行なうことで、マイクロカプセルの外郭が安定し、特に、フレキソ印刷時における耐久性が向上する。 Here, in the present invention, a urea resin-based outer shell is adopted, but it is particularly preferable that the seasoning is performed under conditions of an ambient temperature of 40 to 80 ° C. and an ambient pressure of 1 to 30 atm after the capsule formation for at least 72 hours or more. Use what you did. Immediately after the manufacture, the outer shell of the microcapsule may not be stable due to the transpiration pressure of the encapsulated fragrance, the contained moisture, etc., but by performing seasoning for 72 hours or more, the outer shell of the microcapsule becomes stable. Durability during flexographic printing is improved.
〔試験例〕
本発明に係るマイクロカプセル(試験例1)と本発明とは相違するマイクロカプセル(試験例2、試験例3)とで、経時劣化性について試験をした。
紙料は、l−メントールと冷涼剤とを含む香料を内包させた各例に係るマイクロカプセルを製造し、これを水及びグリセリンを保湿成分として含む薬液に分散させ、ティシュペーパー原紙に塗布したものを用いた。塗布は、すべてフレキソ印刷方式でおこなった。
試験は、各試料を温度50℃、湿度60%の環境下に4週間、暴露した後使用し、その際の清涼感の強さを官能評価5段階で評価する方法とした。
なお、評価は、5:強い清涼感がある。4:清涼感がある、3:清涼感がある、2:清涼感はあまり感じない、1:清涼感をほとんど感じないとした。
結果及び各例にかかる組成などは、下記表1に示す。
[Test example]
The microcapsules according to the present invention (Test Example 1) and the microcapsules different from the present invention (Test Example 2 and Test Example 3) were tested for deterioration over time.
Paper is manufactured by manufacturing microcapsules according to each example in which a fragrance containing l-menthol and a cooling agent is encapsulated, dispersed in a chemical solution containing water and glycerin as a moisturizing component, and applied to tissue paper Was used. All application was done by flexographic printing.
The test was a method in which each sample was used after being exposed for 4 weeks in an environment of a temperature of 50 ° C. and a humidity of 60%, and the strength of the refreshing feeling at that time was evaluated in five stages of sensory evaluation.
Evaluation is 5: There is a strong refreshing feeling. 4: There is a refreshing feeling, 3: There is a refreshing feeling, 2: The feeling of cooling is not felt so much, 1: The feeling of cooling is hardly felt.
The results and the composition according to each example are shown in Table 1 below.
表1から理解されるとおり、本発明のものは香料による清涼感が十分に感じられたが、他の試験例2、試験例3では、清涼感がほとんど感じられない結果となった。この結果から、本発明の構成をとることで、清涼感の持続性が高いティシュペーパーが得られることが知見された。 As can be seen from Table 1, in the present invention, a refreshing feeling due to the fragrance was sufficiently felt, but in the other Test Examples 2 and 3, the refreshing feeling was hardly felt. From this result, it was found that tissue paper having a high refreshing feeling can be obtained by adopting the configuration of the present invention.
Claims (3)
香料を1.0重量%以下の冷涼剤及びl−メントールを含むメントール系香料とし、外郭を尿素樹脂とし、香料含有率が15〜55重量%である、平均粒径6〜30μmのマイクロカプセルを、水及びポリオールを含有する薬液中に分散させ、その薬液をティシュペーパー原紙に対して、線数10〜30線、面積率10〜20%の刷版を用いてフレキソ印刷方式により、10〜35重量%の範囲で塗布することを特徴とするティシュペーパーの製造方法。 A method for producing tissue paper to which a water-based lotion chemical solution containing a microcapsule containing a fragrance is applied,
A microcapsule having an average particle size of 6 to 30 μm, wherein the fragrance is a menthol-based fragrance containing 1.0% by weight or less of a cooling agent and 1-menthol, the outer shell is urea resin, and the fragrance content is 15 to 55% by weight. The chemical solution is dispersed in a chemical solution containing water and a polyol, and the chemical solution is 10 to 35 by a flexographic printing method using a printing plate having 10 to 30 lines and an area ratio of 10 to 20% with respect to the tissue paper base paper. A method for producing tissue paper, wherein the tissue paper is applied in the range of% by weight.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011218522A JP6068787B2 (en) | 2011-09-30 | 2011-09-30 | Tissue paper manufacturing method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011218522A JP6068787B2 (en) | 2011-09-30 | 2011-09-30 | Tissue paper manufacturing method |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013078373A JP2013078373A (en) | 2013-05-02 |
JP6068787B2 true JP6068787B2 (en) | 2017-01-25 |
Family
ID=48525314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011218522A Active JP6068787B2 (en) | 2011-09-30 | 2011-09-30 | Tissue paper manufacturing method |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6068787B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6075867B2 (en) * | 2013-03-28 | 2017-02-08 | 日本製紙クレシア株式会社 | Manufacturing method and manufacturing apparatus of sanitary thin paper |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1346722B1 (en) * | 2000-12-01 | 2008-12-10 | Takeda Pharmaceutical Company Limited | Method for producing preparation containing bioactive substance |
JP3615534B2 (en) * | 2002-12-12 | 2005-02-02 | 大王製紙株式会社 | Lotion tissue paper |
JP2005237745A (en) * | 2004-02-27 | 2005-09-08 | Crecia Corp | Tissue paper |
JP4783640B2 (en) * | 2006-01-31 | 2011-09-28 | 大王製紙株式会社 | Thin paper containing chemicals |
EP2379047B1 (en) * | 2008-12-18 | 2017-03-15 | Firmenich S.A. | Microcapsules and uses thereof |
JP5680291B2 (en) * | 2009-10-07 | 2015-03-04 | 高砂香料工業株式会社 | Cooling sensation agent composition, sensory stimulant composition and use thereof |
JP4681677B1 (en) * | 2010-03-26 | 2011-05-11 | 大王製紙株式会社 | Method for producing secondary roll for tissue paper product and method for producing tissue paper product |
-
2011
- 2011-09-30 JP JP2011218522A patent/JP6068787B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2013078373A (en) | 2013-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW397879B (en) | Wet-like cleaning wipes and like articles comprising a carrier substrate treated with high internal water phase inverse emulsion | |
US7485373B2 (en) | Lotioned tissue product with improved stability | |
KR100542169B1 (en) | Soft tissue obtained by applying a solid hydrophilic lotion | |
ES2338129T3 (en) | TISU PAPER WITH HIGH CAPACITY TO TRANSFER A LOTION. | |
KR101783492B1 (en) | Cooling substrates with hydrophilic containment layer and method of making | |
KR20000016337A (en) | Anti-viral, anhydrous, and mild skin lotions for application to tissue paper products | |
KR20120104210A (en) | Temperature change compositions and tissue products providing a cooling sensation | |
JP6105877B2 (en) | Sanitary tissue paper | |
TWI706069B (en) | Paper treatment agent and paper treating method | |
JP4833936B2 (en) | Tissue paper | |
EP1985755B1 (en) | Tissue paper containing liquid drug | |
JP4916832B2 (en) | Sanitary paper | |
JP6068787B2 (en) | Tissue paper manufacturing method | |
TWI678446B (en) | Paper treating agent | |
JP4783640B2 (en) | Thin paper containing chemicals | |
JP5427339B2 (en) | Chemical tissue-containing tissue paper | |
JP4753544B2 (en) | Tissue paper and tissue paper manufacturing method | |
JP2004285052A (en) | Cosmetic composition | |
JP5363698B2 (en) | Chemical tissue-containing tissue paper | |
JP6684135B2 (en) | Sanitary thin paper manufacturing apparatus and sanitary thin paper manufacturing method | |
JP2007100229A5 (en) | ||
CA2599614C (en) | Use of a volatile rhinological effective composition on fibrous tissues to provide a sensation of sinusoidal relieve | |
ZA200303293B (en) | Oil-based lotions for paper products. | |
US8343534B2 (en) | Tissue including a volatile rhinological composition | |
JP2008297318A (en) | Method for producing cosmetic sheet containing powder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140828 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150805 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150904 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151104 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160422 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160606 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161202 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161226 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6068787 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |